Redeye updates its estimates and valuation following Coala Life’s recent rights issue, securing cSEK55m in growth capital and resulting in a 75% dilution for non-participating shareholders. CEO Dan Pitulia continues to demonstrate his commitment by investing SEK7m in the rights issue. Our revised estimates reflect the recent development in patient ramp-up for remote monitoring (PRM) and the announced cost-saving program. In our updated valuation, we also factor in an anticipated cash injection of SEK12m from the warrants due in Q2 2024 -our new Base case is SEK0.12 (SEK1.3) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Coala Life - Refilled growth capital

© Modular Finance, source Nordic Press Releases